Hodgkin Lymphoma in Children

Trehan, Amita; Singla, Shaveta; Marwaha, Ram Kumar; Bansal, Deepak; Srinivasan, Radhika

doi:10.1097/mph.0b013e318271f587

Cited by 29 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 21 , 22 Children younger than 5 years of age constituted 15% of the current cohort of patients, which is similar to the proportion at other Indian centers. 5 This is in contrast to Western data, which show that less than 5% of patients are under 5 years of age. 20 , 23 - 25 Two thirds of our patients were male, and a similar trend has been reported from other centers in India.…”

Section: Discussionmentioning

confidence: 71%

“… 20 , 23 - 25 Two thirds of our patients were male, and a similar trend has been reported from other centers in India. 4 , 5 , 7 - 10 This phenomenon could be attributed partly to a bias against seeking treatment for female children in Indian society; however, accounting for the trends in other pediatric cancers, such a major difference cannot be explained. 26 Malnutrition is a significant problem in developing countries, and it has been associated with poor outcomes in pediatric malignancies, but it was not a significant prognostic factor in this study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

Radhakrishnan

Dhanushkodi

Ganesan

et al. 2017

JGO

View full text Add to dashboard Cite

PurposePediatric Hodgkin lymphoma (HL) is a highly curable malignancy. Outcomes for pediatric HL may vary between developed and developing countries for multiple reasons. This study was conducted to ascertain the outcomes of children with HL at our center and to identify risk factors for recurrent disease.MethodsWe analyzed the outcomes of 172 consecutive, previously untreated patients with pediatric HL presenting at our center from 2001 to 2010. Patients were treated with either adriamycin, bleomycin, vinblastine, and dacarbazine or adriamycin, bleomycin, vinblastine, cyclophosphamide, vincristine, prednisone, and procarbazine chemotherapy initially, and radiation to bulky sites or a single site of residual disease when appropriate.ResultsThe median duration of follow-up was 77 months. The median age of the patients was 10 years; 127 (74%) of the 172 patients were male. The extent of disease was stage I and II in 59% of the patients. B symptoms were present in 32% of the patients, and 27% had bulky disease. The most common histologic subtype was mixed cellularity (45%). The 5-year overall survival (OS) and progression-free survival (PFS) of the entire cohort were 92.9% and 83.1%, respectively. The 5-year OS rates for patients with stage I, II, III, and IV were 96%, 94.7%, 84%, and 69.8%, respectively. On univariate analysis, advanced stage, response on interim radiologic assessment, and presence of B symptoms significantly predicted inferior PFS and OS. On multivariate analysis, only interim radiologic response significantly predicted PFS (P < .001) and OS (P < .001).ConclusionOverall, the outcomes of patients treated at our center are comparable to those observed in other centers in India and globally.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

Radhakrishnan

Dhanushkodi

Ganesan

et al. 2017

JGO

View full text Add to dashboard Cite

show abstract

“…ABVD, COPP-ABVD, and COPP-ABV are the most commonly used regimens in Indian children; and the studies using these regimens are listed in Table 5 . [ 10 11 12 13 14 ] The EFS reported in these studies range from 50% to 74%; and the OS from 78% to 100%. The best results of 78% EFS at 8 years (and OS of 100%) were reported in the Tata memorial study with the use of ABVD plus IFRT.…”

Section: Discussionmentioning

confidence: 93%

“…[ 9 ] In another study, the ABVE-PC regimen had an EFS of 84% in high-risk patients and 85% in intermediate-risk patients. [ 8 ] Available studies from India indicate ABVD, COPP-ABVD, and COPP-ABV are the regimens commonly used in Indian children;[ 10 11 12 13 14 ] but there is no data on the use of ABVE-PC or BEACOPP. Herein, we report our limited experience with these two regimens in Indian children with intermediate and high-risk HL respectively, and review the literature on the efficacy of these regimens in children.…”

Section: Introductionmentioning

confidence: 99%

ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy

Jayabose

Viswanathan

Kumar

et al. 2016

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Aims:To study the toxicity of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide) and modified-BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in intermediate-risk and high-risk Hodgkin lymphoma patients.Methods:High-risk patients received 4 cycles of modified-BEACOPP (m-BEACOPP) plus 4 cycles of ABVD. Intermediate-risk patients received 4 cycles of ABVE-PC plus 2 cycles of ABVD.Results:From 2010 to 2014, 17 patients received 66 cycles of m-BEACOPP and 9 patients received 40 cycles of ABVE-PC. In the m-BEACOPP and ABVE-PC courses, respectively, significant thrombocytopenia (<50,000/mm3) occurred in 10.6% vs 0% of courses; anemia (Hb. <8 gm/dl) in 27.3% vs 15%; neutropenia (ANC<500/mm3) in 46.9% vs 32.5%; and febrile neutropenia in 33.3% vs. 22.5%. Only episode of documented infection (hepatic abscess) occurred in ABVE-PC. There were no episodes of sepsis, typhlitis or pneumonia in either group. All 26 patients are in remission with a median follow-up of 35 months (range, 17-61); and there have been no relapses. Two of 26 (7.7%) patients failed to achieve rapid early response after 2 cycles and complete remission after 4 cycles of chemotherapy; both achieved remission with more intensive regimens followed by radiation. The remaining 24 patients did not receive radiation therapy.Conclusions:Both m-BEACOPP and ABVE-PC regimens have acceptable toxicity; and thus can be used in most centres with optimum supportive care facilities. They offer promising response rate and relapse free survival without the need for radiation therapy in most patients; and thus may be considered for children with high-risk and intermediate-risk Hodgkin lymphoma.

show abstract

“…Chemotherapy alone is considered as another different technique but still controversial [100]. However, there are various epidemiological profiles from developing countries with excellent outcomes by chemotherapy alone is good in children HL cases [101]. At this time CMT is standard treatment for CHL early patients and radiotherapy is for aggressive cases.…”

Section: Sexmentioning

confidence: 99%

Epidemiological features of Lymphoma in Pakistan

Shabbir

Mengal

Jan

et al. 2019

PAB

View full text Add to dashboard Cite

Lymphoma is a heterogeneous group of malignancies derived from the lymphoid system that accounts for roughly 4 % of cancers worldwide. A significant improvement during the last decade was made possible with the introduction of an anti-CD20 monoclonal antibody, rituximab, which has been utilized widely in the treatment of B cell lymphomas leading to significantly better outcomes, which in part have contributed to the reduced mortality rates. Various factors like lifestyle, genetics, environment, age, ethnicity and gender are risk factors of lymphoma. Other factors include Socioeconomics, marital status, educational background, history of drinking or smoking and obesity. Globally, lymphoma is the sixth most common malignancy. HL is second most common lymphoma in developed countries whereas third most common malignancy in developing countries. NHL is eleventh most occurring cancer in males and eighth most common in female. Lymphoma is more common in men. In Pakistan HL accounts for 4.9% and NHL is approximately 4.7%. Prevalence of lymphoma cancer in Balochistan is about 9.6%.

show abstract

Hodgkin Lymphoma in Children

Abstract: Even though developing countries have a different epidemiological profile, the outcome is good. Chemotherapy alone has shown excellent results in children with HL.

Cited by 29 publications

References 25 publications

Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy

Epidemiological features of Lymphoma in Pakistan

Contact Info

Product

Resources

About